Produced by AVE, it has a high degree of automation, and the front end is equipped with automatic sample delivery device.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Products and Technology Innovation of Urine Dry Chemical Analysis

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Abbott disclosed on Thursday that a cyberattack hit its cancer diagnostics business.

Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026.

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its Alethia® CMV assay. The addition of CMV expands Meridian's existing Alethia menu, which includes C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian's molecular diagnostic offerings in the Canadian market.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and Scotland.